Data Privacy Laws Are Expanding Quickly. What Does That Mean for U.S. Companies?

 

In an era of heightened data privacy consciousness, a wave of new laws is sweeping across the United States, shifting the landscape of digital information management.

From the heartland of Iowa to the scenic landscapes of Montana, states are proactively crafting legislative solutions to safeguard consumer data. Notably, these laws mandate an array of safeguards to ensure that organizations are not only transparent about their data collection practices but also secure in their storage and use of personal information. Data privacy laws also increase scrutiny on the use of AI and encourage due diligence in corporate transactions.

While data privacy practices can be expensive and legally complex, there are several benefits for organizations to adhere to data privacy laws. For example, businesses strengthen consumer trust and avoid significant penalties, both financial and reputational.

As the timeline for implementation spans the next few years, businesses and consumers alike have the opportunity to adapt and prepare.

Hunter Sundbeck, IT Advisory Services Manager at Weaver, has been closely monitoring these developments and shares his observations.

Hunter’s Thoughts:

“Hunter Sundbeck here with a data privacy law update. Over the last several months, we’ve seen several states pass data privacy laws. These are Iowa, Tennessee, Indiana, Montana, and Washington. Iowa’s goes into effect in 2025, Tennessee’s in 2025, Montana’s in 2024, Indiana’s in 2026, and Washington’s My Health My Data Act in March of 2024. Some key considerations from some of these is that Tennessee has an annual requirement of $25 million or more in revenue. Each of these requires a privacy notice to inform consumers about what’s going on with their data that companies are collecting. And every organization collecting information on residents of these states required technical, physical, and administrative safeguards over consumer data and information. If you want to know more about these and upcoming data privacy laws, please feel free to reach out at weaver.com. Thanks, y’all.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More